Orient Pharma Co., Ltd. AI Stock Analysis
Orient Pharma Co., Ltd. (4166) AI Stock Analysis
Orient Pharma Co., Ltd.
(TPEx:4166)
The score is anchored by strong and improving fundamentals: tripling revenue since 2020, expanding operating and net margins, a dramatically deleveraged balance sheet with debt at just 0.08x equity, and earnings now backed by genuine free cash flow. These strengths are tempered by a short profitable history, a still-modest 8.1% return on equity, and some gross margin slippage. The main drag is technical: the shares trade below all key moving averages with a negative MACD, placing them in a defined downtrend, although deeply oversold RSI and stochastic readings hint at scope for a near-term bounce. Valuation at 23.3x earnings is fair rather than compelling, and the lack of a dividend offers no income support. Overall, a fundamentally improving business whose share price has yet to reflect that progress.
Orient Pharma Co., Ltd. (4166) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 5.49B
- Dividend Yield
- ―
- Average Volume (3M)
- 88.52K
- Price to Earnings (P/E)
- 22.8
- Beta (1Y)
- 0.33
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- TW
- Employees
- 173
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Orient Pharma Co., Ltd. Business Overview & Revenue Model
Company Description
Orient Pharma Co., Ltd., established in Taipei, Taiwan, in 2008, is a global pharmaceutical company engaged in the research, development, production, and sales of medicinal products. Its extensive pipeline addresses diverse therapeutic areas, includi...
Orient Pharma Co., Ltd. Financial Statement Overview
Summary
Orient Pharma shows a convincing turnaround across all three statements. Revenue has more than tripled since 2020 to NT$1.40 billion, with operating margin expanding to 18.6% and net income reaching NT$208 million. The balance sheet is the standout: debt cut to NT$196 million (0.08x equity) with equity funding roughly 87% of assets. Cash flow has flipped decisively positive, with operating cash flow of NT$360 million covering net income about 1.7 times. Offsetting these strengths are a short profitable track record, modest 8.1% return on equity against an enlarged capital base, and gross margin erosion to 50.5% from 53.3%.
Income Statement
76PositiveBalance Sheet
84Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.52B | 1.40B | 1.22B | 889.91M | 511.86M | 463.34M |
| Gross Profit | 831.77M | 706.92M | 651.56M | 468.67M | 155.35M | 142.67M |
| EBITDA | 387.56M | 396.67M | 312.81M | 172.40M | 35.37M | -39.21M |
| Net Income | 235.25M | 208.44M | 107.37M | 22.29M | -28.76M | -102.65M |
Balance Sheet | ||||||
| Total Assets | 3.01B | 2.94B | 2.52B | 2.56B | 1.85B | 1.76B |
| Cash, Cash Equivalents and Short-Term Investments | 585.05M | 627.40M | 109.30M | 113.12M | 97.23M | 151.72M |
| Total Debt | 189.61M | 195.97M | 546.78M | 716.93M | 508.21M | 415.33M |
| Total Liabilities | 353.90M | 374.88M | 733.00M | 892.18M | 757.65M | 647.90M |
| Stockholders Equity | 2.66B | 2.56B | 1.79B | 1.67B | 1.09B | 1.12B |
Cash Flow | ||||||
| Free Cash Flow | 201.55M | 324.32M | 169.60M | -176.51M | -17.54M | -123.56M |
| Operating Cash Flow | 291.69M | 360.13M | 197.01M | -102.99M | 11.38M | -53.56M |
| Investing Cash Flow | -209.76M | -73.07M | -22.48M | -88.02M | -29.09M | 55.81M |
| Financing Cash Flow | 285.18M | 217.75M | -173.36M | 197.90M | -36.79M | 79.11M |
Orient Pharma Co., Ltd. Peers Comparison
Overall Rating
- TW:416670Outperform
TW:173464Neutral
TW:474664Neutral
TW:415752Neutral
TW:411948Neutral
TW:678541Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4166 | 70Outperform | TWD 5.47B | 22.78 | ― | ― | ― | ― |
| TW:1734 | 64Neutral | TWD 6.07B | 17.33 | ― | 3.13% | 2.44% | -3.96% |
| TW:4746 | 64Neutral | TWD 5.43B | 11.42 | ― | 6.61% | -2.71% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4157 | 52Neutral | TWD 5.78B | 37.38 | ― | ― | 530.40% | ― |
| TW:4119 | 48Neutral | TWD 5.85B | 95.69 | ― | 1.55% | -18.83% | -87.54% |
| TW:6785 | 41Neutral | TWD 5.11B | -73.49 | ― | 0.12% | -57.57% | -312.45% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4166 | Orient Pharma Co., Ltd. | 22.55 | -2.05 | -8.33% | |
| TW:1734 | Sinphar Pharmaceutical Co. Ltd. | 30.15 | 1.76 | 6.19% | |
| TW:4119 | SCI Pharmtech Corp. | 48.50 | -0.61 | -1.25% | |
| TW:4157 | TaiGen Biopharmaceuticals Holdings Limited | 8.29 | -1.23 | -12.92% | |
| TW:4746 | Formosa Laboratories, Inc. | 45.40 | -15.89 | -25.92% | |
| TW:6785 | Alar Pharmaceuticals Inc | 80.10 | -174.64 | -68.56% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026